Final Results

For the year ended 30 June 2026, Fidelity Emerging Markets Limited reported a 99.3% share-price total return and a 92.3% NAV total return, versus a 48.2% benchmark return. The company said five-year performance comfortably cleared the hurdle for its conditional tender offer and that its enhanced investment toolkit added significant value. The Board announced a final dividend of $0.33 per Participating Preference Share.

Analysis

The key issue is whether exceptional relative performance is repeatable or primarily a one-off portfolio outcome. The share-price return materially exceeding NAV return is consistent with discount narrowing, but the report does not provide the starting/ending discount or return attribution; verify both before treating the share price as evidence of sustained stock-picking alpha. A conditional tender offer hurdle being met may support realization of some discount, but the terms, timing, size and shareholder eligibility matter more than the hurdle result itself. A tender can also create a temporary supply overhang if holders sell in anticipation or if the offer is unattractive.

Near term, the main catalyst is publication of tender mechanics and portfolio attribution. Over 1–3 months, the test is whether NAV performance remains strong after separating market beta, currency and country/sector concentration from security selection. Over 6–18 months, a broad emerging-markets reversal could expose the risk of extrapolating a single strong year; concentrated exposures and currency weakness can erase gains quickly. The dividend should not be read as evidence of recurring distribution capacity without coverage and policy details.

Contrarian view: after a sharp rerating, investors may be paying for past alpha just as the discount benefit is largely captured. No clean directional trade is justified without current discount, tender terms, holdings and attribution.

Key Decisions for Investors

• Do not chase the rally on headline performance alone. Check the current discount/premium to NAV against its own history and comparable investment trusts; discount normalization may already account for much of the upside.
• Treat the tender as a conditional catalyst, not a completed value unlock. Reassess when the Board discloses price, size, timetable and eligibility; an unattractive offer or meaningful pre-tender selling would weaken the case.
• Request portfolio attribution by country, sector, currency and security selection, plus concentration and cash/derivative exposures. If returns are mainly broad EM beta, compare exposure with diversified emerging-markets vehicles rather than paying a persistent trust discount premium.
• Falsification watch: sustained NAV underperformance versus the benchmark over the next 1–3 months, a material widening of the discount, or tender terms that fail to deliver a credible exit mechanism would argue against a positive rerating thesis.